Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Laryngoscope|January 22, 2010
Photodynamic therapy of cottontail rabbit papillomavirus-induced papillomas in a severe combined immunodeficient mouse xenograft systemRichard G Lee, Mark A Vecchiotti, John Heaphy, et al.
Urology|January 1, 2013
Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access programAlfonsus J M van den Eertwegh, Pierre Karakiewicz, Sevil Bavbek, et al.
American Journal of Hematology|June 19, 2009
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplantPaul M Barr, Hillard M Lazarus, Brenda W Cooper, et al.
European Urology|February 3, 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta, Emiliano Calvo, Miguel A Climent, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
Photochemistry and Photobiology|January 29, 2008
Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4Malcolm S Ke, Liang-yan Xue, Denise K Feyes, et al.
Mayo Clinic Proceedings|March 5, 2008
Outcomes of patients with stable heart failure undergoing elective noncardiac surgeryYe Olivia Xu-Cai, Daniel J Brotman, Christopher O Phillips, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Clinical Breast Cancer|November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.
Breast Cancer (Tokyo, Japan)|February 14, 2013
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2Shinzaburo Noguchi, Norikazu Masuda, Hiroji Iwata, et al.
Pageof 3